arcc-4

ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide and it is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1].

ARCC 4 negative control is a negative control for ARCC 4. Binds androgen receptors (AR) without inducing degradation.

ABM-14, a ligand for the androgen receptor (AR), is utilized as a targeting agent in PROTAC. By binding to a ligand for the von Hippel-Lindau protein (VHL) via a linker, ABM-14 forms ARCC-4, which facilitates the degradation of AR.